On September 10, 2026, two FDA regulatory tracks governing peptide compounds moved in opposite directions simultaneously, producing a binary landscape for compounding pharmacies that did not exist eighteen months earlier. The agency's Pharmacy Compounding Advisory Committee has narrowly recommended six unapproved wellness peptides for small-scale 503A compounding, overriding the FDA's own staff reviewers. In parallel, the agency has proposed to permanently bar semaglutide, tirzepatide, and liraglutide from the 503B Bulks List that governs large-scale outsourcing facilities. One pathway opens toward experimental substances. The other slams shut on the most commercially successful peptide therapeutics ever marketed.

A Panel Reshaped, a Recommendation Without Force

The PCAC's July 23–24 vote covered BPC-157, KPV, TB-500, MOTS-c, Semax, and epitalon. The panel backed all six for potential 503A Bulks List inclusion despite FDA staff recommending against every candidate on the docket, as reported by the American Journal of Managed Care. None of the six holds FDA drug approval. None has completed the large-scale human trials that approval requires. FDA reviewers cited limited human safety data during the proceedings.

The committee's composition helps explain the divergence from staff guidance. HHS Secretary Robert F. Kennedy Jr. added eight new members ahead of the vote, six of whom operate clinics that dispense the compounds under review, a conflict that drew the label the 'grifter' panel from critics inside and outside the agency.

Scott Brunner, CEO of the Alliance for Pharmacy Compounding, cautioned that the vote changes nothing in the near term. The FDA must still decide whether to accept the nonbinding recommendations and, if it does, proceed through notice-and-comment rulemaking: a proposed rule, a public comment period, and a final rule. Until that process concludes, compounding BPC-157 or TB-500 remains illegal for U.S. pharmacies. The fda panel's narrow vote leaves bpc-157 and semax in regulatory limbo for an indeterminate period, with no published timeline for the agency's next step.

The commercial pressure behind the vote is real. The FDA moved roughly nineteen peptides to its Category 2 restricted list in 2023, citing safety concerns and absent human trial data. Kennedy announced in February 2026 that approximately fourteen of those nineteen would be reclassified toward compounding eligibility. The PCAC vote represents the first formal procedural step toward that reclassification, but only for the subset that reached the committee's agenda.

Closing the 503B Door on GLP-1s

The GLP-1 exclusion proposal, announced April 30, 2026, operates through a different legal mechanism and targets a different class of operator. The 503B pathway permits outsourcing facilities to manufacture compounded drugs at scale, without individual patient prescriptions, provided the bulk substances appear on the FDA's approved list. The proposed rule would remove semaglutide, tirzepatide, and liraglutide from that list permanently, eliminating both the bulks-list and shortage-list pathways. Pharmacy Times reported that the agency framed the exclusion around clinical need: "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need."

The practical effect is near-total. Demand-driven shortages beginning in 2022 had enabled widespread compounding at roughly $150 to $300 per month, compared with branded pricing above $1,000. The FDA declared those shortages resolved. The Outsourcing Facilities Association sought preliminary injunctions in federal court and lost. The proposed rule now converts that enforcement posture into codified regulation. Safety data buttresses the agency's position: more than 455 adverse-event reports tied to compounded semaglutide and more than 320 linked to tirzepatide, alongside dosing errors involving multidose vials and counterfeit supply chains.

The FDA has paired the exclusion proposal with enforcement aimed at the prescribing pipelines that fed the compounding market: fda slaps 30 telehealth firms with warning letters over compounded glp-1 marketing. The proposal remains open for public comment and is not yet final law, but the agency's language leaves little room for reversal.

Two Procedural Realities

The gap between the two actions is structural. The wellness-peptide recommendation is an advisory input with no legal force until the FDA adopts it and completes rulemaking. The GLP-1 exclusion is a formal proposed rule with a defined comment window and a clearer path to finality. In regulatory terms, the GLP-1 ban is closer to becoming binding law than the peptide compounding authorization is to becoming permissible.

For pharmacy operators, the divergence creates an unusual planning problem. A 503A facility considering peptide compounding must wait for a final rule that may take months to materialize, with no guarantee the FDA will accept the panel's recommendation. A 503B facility that built revenue around compounded GLP-1s faces the opposite risk: a rule that could eliminate its product line within a similar timeframe.

Ilisa Bernstein, a former FDA official and pharmacist specializing in drug and pharmacy policy, told NPR that the agency bears a "responsibility to ensure that there's some level of safety before they become widely available," while acknowledging that once compounding is authorized, "any pharmacy can compound these products." The distinction between compounding eligibility and drug approval remains critical. Even if the 503A list is finalized, BPC-157 and TB-500 will not carry FDA approval. They will carry a permission to be mixed in a pharmacy under a prescription.

The FDA has set no decision date for either action. Kennedy's HHS has signaled enthusiasm for the wellness-peptide track. The agency's career staff signaled the opposite during the PCAC proceedings. The GLP-1 track faces no comparable internal disagreement. One path is contested. The other is nearly settled. Both remain, as of September 10, proposals and recommendations rather than binding law.